appreci
epidemiolog
acut
pulmonari
infect
requir
pediatr
intens
carereview
sign
symptom
bronchiol
pneumoniareview
host
defens
mechan
acut
pulmonari
infectionsreview
common
etiolog
bronchiolitisreview
common
etiolog
pneumoniaunderstand
pathophysiolog
bronchiol
pneumonia
childrenunderstand
treatment
option
includ
mode
ventil
bronchiol
pneumoniaunderstand
effect
manag
strategi
parapneumon
effus
empyema
acut
lower
respiratori
infect
common
caus
morbid
infant
children
time
requir
intens
care
mechan
ventil
viral
bronchiol
bacteri
pneumonia
account
major
lower
respiratori
tract
infect
lead
respiratori
insuffici
pediatr
intens
care
admiss
twentyseven
percent
children
requir
mechan
ventil
least
h
pediatr
intens
care
unit
diagnos
bronchiol
diagnosi
pneumonia
median
length
time
intub
acut
pulmonari
infect
lead
respiratori
failur
approxim
day
viral
bronchiol
remain
lead
caus
hospit
admiss
infanc
frequent
caus
acut
respiratori
failur
children
admit
pediatr
intens
care
unit
north
america
pneumonia
children
younger
year
age
annual
incid
case
per
commun
acquir
pneumonia
also
lead
sever
respiratori
compromis
especi
children
preexist
diseas
detail
understand
divers
etiolog
distinct
clinic
cours
acut
pulmonari
infect
essenti
pediatr
critic
care
praction
chapter
focu
bronchiol
pneumonia
two
lead
caus
pulmonari
infect
lead
picu
admiss
approxim
one
third
children
develop
bronchiol
first
year
life
infant
unit
state
requir
hospit
although
hospit
rate
increas
last
three
decad
mortal
remain
low
overal
mortal
rate
high
high
risk
infant
death
occur
infant
younger
month
age
comorbid
prematur
congenit
heart
diseas
congenit
acquir
lung
diseas
immunodefici
mortal
rsv
bronchiol
continu
declin
better
intens
care
use
prevent
therapi
respiratori
syncyti
viru
rsv
first
isol
still
repres
major
caus
bronchiol
caus
virus
includ
parainfluenza
adenoviru
enteroviru
influenza
recent
human
metapneumoviru
human
bocaviru
hbov
northern
hemispher
rsv
outbreak
occur
octob
june
human
metapneumoviru
hmpv
recent
identifi
caus
agent
bronchiol
case
possibl
surpass
parainfluenza
second
common
etiolog
preval
slightli
higher
late
winter
spring
parainfluenza
infect
peak
month
age
repres
approxim
case
bronchiol
parainfluenza
endem
throughout
year
especi
common
late
spring
male
time
like
requir
hospit
bronchiol
like
sever
diseas
xlink
genet
trait
result
reduc
toler
hypoxia
postul
would
consist
observ
increas
mortal
newborn
male
infant
respiratori
distress
syndrom
virtual
children
age
two
infect
rsv
children
age
five
infect
hmpv
children
age
nine
infect
hbov
male
infant
like
requir
hospit
usual
manifest
sever
diseas
remaind
discuss
bronchiol
divid
rsv
nonrsv
bronchiol
although
etiolog
agent
may
differ
clinic
cours
often
similar
rsv
introduc
onto
nasal
conjunctiv
mucos
surfac
caus
profus
rhinorrhea
within
day
first
month
life
passiv
acquir
matern
antibodi
protect
howev
matern
antibodi
titer
gradual
decreas
infant
becom
suscept
sever
diseas
cellbound
iga
may
develop
help
clear
viru
circul
igg
direct
glycoprotein
g
fusion
f
protein
oper
syncytia
format
viral
surfac
develop
sever
day
later
infant
less
month
age
appear
induc
weaker
antibodi
respons
like
due
presenc
matern
antibodi
virusspecif
ige
respiratori
tract
associ
diseas
sever
often
complet
effect
immun
respons
induc
thu
reinfect
possibl
even
season
epitheli
cell
alveolar
macrophag
key
activ
cellular
immun
although
cell
enhanc
viral
clear
also
contribut
airway
inflamm
releas
cytokin
chemokin
includ
interleukin
il
tumor
necrosi
macrophageinflammatori
protein
mip
rant
regul
upon
activ
normal
cell
express
secret
releas
cytokin
chemokin
believ
partial
respons
airway
inflamm
hyperreact
effect
mediat
persist
beyond
acut
infect
contribut
prolong
pulmonari
dysfunct
regul
inflammatori
cascad
releas
chemokin
cytokin
contributori
airway
inflamm
hyperreact
children
requir
mechan
ventil
lower
peripher
cell
count
compar
hospit
infant
requir
mechan
ventil
infant
demonstr
low
cell
prolif
respons
interferon
product
requir
initi
cellular
immun
length
time
requir
mechan
ventil
found
invers
relat
product
role
cytokin
profil
express
ratio
controversi
studi
ratio
decreas
polyclon
stimul
hospit
infant
rsv
howev
recent
studi
shown
normal
ratio
follow
polyclon
stimul
neutrophil
predomin
cell
found
airway
infant
rsv
bronchiol
elev
level
found
high
concentr
nasal
secret
infect
children
act
neutrophil
chemoattract
evid
cellular
induc
injuri
seen
postmortem
examin
peribronchi
lymphocyt
infiltr
bronchial
epitheli
necrosi
typic
present
infant
typic
present
tachypnea
rhinorrhea
cough
lowgrad
fever
irrit
poor
feed
vomit
respiratori
rate
greater
breath
per
minut
often
associ
room
air
satur
less
infant
may
also
tachycardia
mild
conjunct
otiti
media
pharyng
lowgrad
fever
usual
persist
day
addit
infant
may
develop
metabol
acidosi
poor
calor
fluid
intak
apnea
often
first
present
symptom
rsv
bronchiol
small
infant
etiolog
apnea
remain
unknown
howev
like
relat
immatur
respiratori
control
center
brainstem
incid
apnea
infant
bronchiol
approxim
heterogen
natur
rsv
induc
lung
diseas
caus
atelectasi
area
overdistens
other
chest
roentgenogram
often
show
hyperinfl
flatten
diaphragm
patchi
peribronchi
infiltr
atelectasi
especi
right
upper
lobe
often
seen
infant
may
high
lung
volum
function
residu
capac
often
twice
normal
decreas
dynam
complianc
increas
airway
resist
lead
mark
increas
work
breath
often
wors
expir
lower
airway
obstruct
alter
ga
exchang
hypoxemia
secondari
ventilationperfus
mismatch
anatom
differ
young
infant
older
children
contribut
sever
diseas
young
due
highli
compliant
cartilagin
chest
wall
poor
thorac
musculatur
infant
chest
wall
difficulti
counter
lung
inher
tendenc
toward
collaps
lead
greater
propens
small
infant
toward
atelectasi
compar
older
children
absenc
effect
collater
ventil
infant
also
contribut
develop
atelectasi
impair
ga
exchang
cellular
debri
small
airway
peribronchi
edema
increas
airway
resist
lead
wheez
predomin
symptom
infant
despit
potenti
sever
impair
lung
function
hospit
infant
improv
within
day
typic
week
normal
respiratori
rate
oxygen
ventil
chest
radiograph
usual
normal
day
howev
infant
protract
cours
mild
respiratori
symptom
persist
month
viral
respiratori
infect
link
develop
asthma
later
childhood
tucson
children
respiratori
studi
group
prospect
follow
year
infant
bronchiol
found
increas
risk
subsequ
wheez
episod
infant
increas
risk
sever
rsv
diseas
chronic
lung
diseas
due
prematur
bronchopulmonari
dysplasia
cystic
fibrosi
congenit
heart
diseas
immunodefici
children
cystic
fibrosi
rsv
account
symptomat
infect
hospit
infant
less
year
infant
requir
mechan
ventil
studi
hospit
infant
congenit
heart
diseas
infect
rsv
requir
intens
care
receiv
mechan
ventil
die
children
undergon
hematopoiet
stem
cell
transplant
develop
rsv
infect
extrem
high
mortal
despit
mechan
ventil
antivir
therapi
environment
factor
crowd
passiv
exposur
tobacco
smoke
lack
breastfeed
associ
develop
sever
diseas
compar
nation
averag
nativ
american
alaskan
children
younger
year
age
higher
rate
infect
three
subtyp
human
parainfluenza
virus
frequent
isol
children
bronchiol
commonli
caus
croup
similar
rsv
cellmedi
hyperrespons
viral
antigen
virusspecif
ige
respons
observ
children
parainfluenza
bronchiol
upper
airway
edema
concomit
obstruct
symptom
may
present
children
infect
parainfluenza
signific
likelihood
develop
asthma
later
life
human
metapneumovirus
hmpv
group
rna
virus
paramyxovirida
famili
identifi
human
hmpv
appear
second
common
caus
bronchiol
children
throughout
world
major
children
born
matern
hmpv
specif
igg
wane
around
month
age
age
five
essenti
children
expos
hmpv
neutral
antibodi
hmpv
two
subgroup
b
group
sever
clinic
symptom
clinic
present
children
viru
similar
rsv
pulmonari
inflamm
gener
peak
day
includ
interstiti
edema
inflammatori
cell
infiltr
bronchiol
alveoli
inflammatori
chang
persist
day
half
infect
children
month
age
infect
primarili
winter
month
human
bocaviru
hbov
recent
discov
amino
acid
sequenc
new
member
parvovirida
famili
found
close
relat
bovin
parvoviru
canin
minut
viru
henc
name
bocaviru
bo
bovin
ca
canin
detect
hbov
respiratori
tract
symptomat
children
absenc
detect
nonsymptomat
control
strongli
suggest
viru
role
respiratori
infect
children
coinfect
commonli
describ
sampl
remain
unclear
hbov
primari
pathogen
act
exacerb
viral
ill
pathogenesi
hbov
well
describ
high
occurr
wheez
lower
respiratori
tract
symptom
children
infect
viru
specul
viru
may
signific
contributor
asthma
exacerb
major
infect
children
rhinorrhea
cough
wheez
howev
diarrhea
report
children
children
high
viral
load
hbov
detect
serum
suggest
potenti
diseas
beyond
respiratori
tract
influenza
includ
novel
influenza
strain
influenza
b
caus
clinic
pictur
consist
bronchiol
small
infant
virus
may
caus
sever
multisystem
diseas
discuss
greater
detail
viral
pneumonia
section
rapid
diagnost
assay
avail
earli
detect
mani
virus
older
assay
antigenbas
includ
indirect
immunofluorescencedirect
immunofluoresc
ifadfa
enzym
immunoassay
eia
optic
immunoassay
oia
neuraminidas
activ
assay
although
still
wide
use
inexpens
technic
simpl
low
specif
sensit
molecular
assay
becom
new
gold
standard
respiratori
viru
detect
replac
tissu
cultur
may
take
day
publish
sensit
specif
approach
compar
tissu
cultur
antigen
assay
assay
gener
use
polymeras
chain
reaction
pcr
amplif
signific
advanc
assay
made
simplifi
perform
assay
decreas
requir
time
import
caus
fals
neg
test
result
remain
poor
specimen
handl
inadequ
sampl
collect
aid
cohort
hospit
patient
serolog
detect
respiratori
virus
rare
clinic
use
regardless
viral
etiolog
bronchiol
support
care
remain
mainstay
treatment
supplement
humidifi
oxygen
frequent
need
due
mani
infant
oblig
nasal
breather
frequent
nasal
suction
may
benefici
maintain
unobstruct
upper
airway
affect
infant
child
often
unabl
take
adequ
fluid
complic
increas
insens
loss
respiratori
tract
henc
intraven
fluid
may
requir
infant
children
sever
respiratori
distress
kept
npo
event
respiratori
failur
ensu
endotrach
intub
requir
antibiot
routin
indic
previous
healthi
children
infect
rsv
progress
diseas
leukocytosi
persist
fever
consolid
radiograph
system
toxic
prompt
evalu
bacteri
coinfect
use
empir
antibiot
support
therapi
mainstay
treatment
bronchiol
ribavirin
bronchodil
corticosteroid
shown
benefit
secondari
bacteri
infect
rare
high
risk
patient
often
requir
close
monitor
care
intens
care
unit
includ
infant
less
week
age
infant
histori
prematur
congenit
heart
diseas
bronchopulmonari
dysplasia
immunodefici
neurolog
diseas
infant
rsv
bronchiol
typic
combin
hyperinfl
pulmonari
infiltr
atelectasi
therefor
one
mode
ventil
recommend
infant
noninvas
posit
pressur
niipp
mode
cpap
bipap
may
attempt
infant
primari
respiratori
embarrass
secondari
atelectasi
howev
may
suitabl
diseas
process
appear
sever
protract
prolong
use
nipp
may
make
feed
difficult
caus
breakdown
facial
tissu
difficult
maintain
without
signific
sedat
compromis
ventil
infant
requir
endotrach
intub
mode
mechan
ventil
tailor
predomin
lung
patholog
present
ie
atelectasi
versu
hyperinfl
children
signific
air
trap
may
need
mechan
ventil
similar
child
asthma
provid
low
respiratori
rate
longer
inspir
exhal
time
typic
infant
lose
function
residu
capac
frc
atelectasi
alveolar
infiltr
therefor
despit
air
trap
infant
often
need
peep
adjust
recruit
alveoli
return
frc
normal
set
elev
pulmonari
vascular
resist
pvr
may
occur
infant
congenit
heart
diseas
bronchopulmonari
dysplasia
lower
pvr
tradit
method
maintain
oxygen
deep
sedat
muscl
relax
even
nitric
oxid
may
indic
ribavirin
fdaapprov
antivir
drug
rsv
ribavirin
inhibit
viral
replic
activ
rsv
influenza
b
adenovirus
hepat
virus
lower
respiratori
tract
diseas
ribavirin
typic
administ
via
aerosol
metaanalysi
studi
involv
ribavirin
discourag
consist
common
clinic
experi
ribavirin
improv
clinic
outcom
therapi
target
attenu
virusinduc
inflammatori
cascad
also
disappoint
corticosteroid
administr
associ
reduct
clinic
score
need
hospit
length
hospit
routin
use
corticosteroid
given
via
rout
intraven
enter
aerosol
indic
except
patient
preexist
chronic
lung
diseas
bronchodil
shown
clear
benefit
patient
acut
rsv
bronchiol
random
control
trial
involv
infant
evalu
effect
salbutamol
albuterol
bronchiol
show
effect
remain
three
studi
demonstr
small
transient
improv
acut
clinic
score
although
routin
use
bronchodil
therapi
recommend
becom
accept
practic
attempt
see
individu
infant
beta
agonist
respons
clinic
respons
seen
trial
beta
agonist
use
discontinu
five
random
trial
involv
infant
evalu
effect
nebul
adrenalin
epinephrin
bronchiol
show
clinic
improv
reduct
oxygen
requir
respiratori
rate
wheez
decreas
pulmonari
vascular
resist
two
studi
show
lower
hospit
admiss
rate
earlier
discharg
cochran
systemat
review
suggest
potenti
benefit
epinephrin
administr
howev
subsequ
studi
support
routin
use
albuterol
clinic
trial
select
infant
seem
reason
nebul
hyperton
salin
use
treat
hospit
well
ambulatori
children
viral
bronchiol
variabl
success
recent
cochran
metaanalysi
nebul
hyperton
salin
shown
improv
clinic
score
decreas
hospit
durat
sever
studi
evalu
benefit
surfact
nitric
oxid
sever
respiratori
distress
result
inconclus
current
support
routin
use
heliox
mixtur
oxygen
helium
lower
viscos
air
use
success
case
airway
obstruct
croup
airway
surgeri
asthma
reduc
respiratori
effort
period
airway
compromis
sever
studi
shown
improv
respiratori
distress
score
patient
heliox
continu
posit
airway
pressur
obviat
need
intub
mechan
ventil
palivizumab
neutral
human
mous
monoclon
antibodi
direct
rsvf
glycoprotein
licens
food
drug
administr
fda
prematur
infant
infant
bronchopulmonari
dysplasia
random
doubl
blind
placebo
control
impactrsv
trial
involv
high
risk
infant
found
signific
reduct
hospit
except
rare
anaphylaxi
signific
advers
effect
observ
palivizumab
approv
use
infant
congenit
heart
diseas
cardiac
synagi
studi
group
includ
children
congenit
heart
diseas
random
doubl
blind
placebo
control
trial
found
rel
reduct
rsv
associ
hospit
death
attribut
palivizumab
sinc
cardiopulmonari
bypass
decreas
serum
drug
concentr
recommend
addit
dose
given
follow
surgeri
continu
protect
desir
palivizumab
use
prevent
therapi
infant
chronic
lung
diseas
congenit
heart
diseas
cardiopulmonari
bypass
significantli
lower
serum
level
palivizumab
redos
follow
surgeri
continu
protect
desir
palivizumab
administ
intramuscularli
mgkg
everi
day
total
five
dose
rsv
season
gener
novemb
march
high
risk
infant
infant
children
develop
rsv
infect
continu
receiv
prophylaxi
follow
recoveri
natur
acquir
antibodi
fulli
protect
motavizumab
new
enhanc
potenc
human
rsv
monoclon
antibodi
demonstr
time
greater
neutral
activ
rsv
complet
phase
iii
trial
motavizumab
found
equal
palivizumab
prevent
rsv
hospit
superior
palivizumab
reduct
rsvspecif
outpati
medic
attend
lower
respiratori
tract
infect
malri
sign
symptom
pneumonia
nonspecif
may
occult
young
infant
children
often
fever
chill
headach
malais
restless
irrit
gastrointestin
complaint
abdomin
pain
distent
emesi
may
also
present
young
children
symptom
often
preced
minor
upper
respiratori
tract
infect
character
lowgrad
fever
rhinorrhea
signific
involv
lower
respiratori
tract
tachypnea
dyspnea
cough
nasal
flare
grunt
retract
may
seen
older
child
may
demonstr
product
sputum
complain
pleurit
chest
pain
auscult
chest
rale
andor
decreas
breath
sound
might
heard
area
consolid
pleural
effus
howev
due
short
path
transmiss
breath
sound
small
chest
size
infant
breath
sound
may
decreas
even
presenc
effus
children
pleural
irrit
might
prefer
lie
affect
side
leg
flex
may
complain
radiat
pain
neck
shoulder
abdomen
commun
acquir
pneumonia
cap
common
time
seriou
infect
children
incid
cap
case
per
children
less
year
age
case
per
children
year
age
exact
preval
etiolog
agent
caus
pediatr
pneumonia
difficult
ascertain
often
difficult
differenti
viral
bacteri
pneumonia
base
sole
clinic
examin
specif
pathogen
caus
cap
determin
approxim
onethird
children
use
commonli
avail
cultur
antigen
detect
serolog
techniqu
blood
cultur
yield
pathogen
infant
children
bacteri
cap
mani
children
undergo
viral
test
often
unnecessari
inher
limit
gener
thought
virus
account
approxim
cap
children
age
year
approxim
cap
preschool
children
age
year
viral
caus
declin
school
age
adolesc
child
bacteri
caus
streptococcu
pneumonia
mycoplasma
becom
import
pathogen
fig
overal
bacteria
account
communityacquir
pneumonia
likelihood
infect
differ
bacteria
vari
age
newborn
period
organ
matern
genit
tract
like
caus
includ
group
b
streptococcu
escherichia
coli
enter
gramneg
bacilli
listeria
chlamydia
older
infant
streptococcu
pneumonia
becom
signific
caus
remain
year
age
group
streptococcu
staphylococcu
aureu
uncommon
caus
moraxella
catarrali
common
caus
upper
respiratori
tract
diseas
rare
caus
pneumonia
infant
pertussi
bacteri
coinfect
children
older
year
age
streptococcu
pneumonia
remain
common
caus
hemophilu
influenza
type
b
hib
recent
streptococcu
pneumonia
decreas
significantli
caus
cap
due
widespread
use
effect
vaccin
difficult
determin
etiolog
agent
caus
pneumonia
microbi
agent
identifi
bacteria
isol
older
child
young
adolesc
atyp
pneumonia
mycoplasma
chlamydia
becom
preval
viral
caus
less
common
rare
bacteri
pneumonia
occur
anim
contact
includ
francisella
tularensi
rabbit
chlamydia
psittaci
parrot
bird
coxiella
burnetii
sheep
salmonella
choleraesui
pig
children
congenit
anatom
defect
immunodefici
genet
disord
increas
risk
bacteri
viral
fungal
pneumonia
airway
normal
steril
sublaryng
area
lung
parenchyma
sever
protect
mechan
includ
anatom
mechan
factor
local
immun
defens
system
immun
respons
microb
filter
nasal
hair
expel
airway
epiglott
reflex
cough
reflex
mucociliari
apparatu
immunoglobulin
iga
predomin
immunoglobulin
present
upper
respiratori
tract
iga
abl
bind
two
antigen
simultan
form
larg
antigenantibodi
complex
manner
microb
neutral
remov
ciliari
clearanc
thu
prevent
microbi
bind
epithelium
lower
tract
immunoglobulin
g
igg
provid
humor
protect
opson
microb
phagocytosi
neutrophil
macrophag
activ
complement
cascad
neutral
bacteri
endotoxin
alveolar
macrophag
produc
superoxid
anion
hydrogen
peroxid
hydroxyl
radic
serv
import
role
host
defens
howev
uncontrol
product
lead
lung
injuri
addit
oxygen
radic
number
cytokin
produc
alveolar
macrophag
includ
tnf
transform
growth
chemotact
factor
platelet
deriv
growth
factor
mcsf
cytokin
play
central
role
phagocyt
recruit
activ
infect
occur
one
defens
mechan
alter
inoculum
larg
pathogen
typic
gain
entri
inhal
aerosol
materi
aspir
resist
organ
inhabit
upper
airway
less
frequent
pneumonia
occur
via
hematogen
spread
pneumonia
occur
one
host
defens
mechan
alter
virus
enhanc
host
suscept
bacteri
pathogen
affect
clear
mechan
weaken
host
immun
respons
children
bacteri
pneumonia
signific
portion
concurr
preced
viral
infect
viral
infect
may
predispos
bacteri
superinfect
reduc
clearanc
mechan
weaken
host
immun
respons
pathogen
enter
lower
airway
evok
exud
consolid
pulmonari
tissu
initi
hyperemia
lung
parenchyma
due
vascular
engorg
capillari
leak
caus
exud
intraalveolar
fluid
accumul
fibrin
deposit
airway
infiltr
neutrophil
consolid
caus
decreas
lung
complianc
vital
capac
total
reduct
surfac
area
avail
ga
exchang
physiolog
shunt
vq
mismatch
occur
increas
blood
flow
poorli
ventil
segment
lung
result
hypoxia
compensatori
hypox
vasoconstrict
may
occur
attempt
reduc
vq
mismatch
hypoxia
especi
local
area
consolid
treatment
resolut
consolid
occur
day
exud
undergo
enzymat
digest
either
reabsorb
remov
cough
bacteri
infect
extend
pleural
caviti
empyema
may
result
streptococcu
pneumonia
gramposit
diplococcu
frequent
found
upper
respiratori
tract
capsular
serotyp
infect
caus
serotyp
common
bacteri
caus
pneumonia
occur
peak
age
month
typic
caus
lobar
segment
consolid
may
manifest
patchi
infiltr
infant
pleural
effus
occur
children
requir
hospit
fig
pneumatocoel
format
rare
hemolyt
urem
syndrom
associ
neuraminidaseproduc
strain
streptococcu
pneumonia
common
bacteri
caus
pneumonia
treatment
typic
penicillin
cephalosporin
emerg
resist
may
requir
initi
therapi
vancomycin
hospit
patient
parenter
therapi
gener
need
h
fever
resolv
follow
complet
day
enter
therapi
pneumococc
conjug
vaccin
pcv
develop
confer
immun
serotyp
pcv
prevnar
licens
use
unit
state
pcv
recent
introduc
replac
pcv
pcv
highli
effect
reduc
hospit
among
children
younger
year
pneumococc
pneumonia
pcv
recommend
univers
children
younger
month
age
older
children
high
risk
due
underli
diseas
high
risk
children
includ
sickl
cell
diseas
type
function
asplenia
human
immunodefici
primari
immunodefici
children
receiv
immunosuppress
therapi
children
chronic
pulmonari
cardiac
diseas
pcv
avail
risk
children
need
expand
serotyp
coverag
children
sickl
cell
diseas
function
asplenia
continu
receiv
antibiot
prophylaxi
regardless
whether
receiv
pneumococc
vaccin
approxim
infant
born
chlamydia
trachomatisinfect
mother
becom
infect
one
anatom
site
includ
conjunctiva
nasopharynx
rectum
vagina
infant
nasopharyng
infect
develop
pneumonia
infant
usual
present
week
age
cough
congest
absenc
fever
cough
often
interfer
abil
feed
infant
gener
tachypnea
rale
examin
chest
xray
frequent
show
hyperinfl
peripher
eosinophilia
may
present
c
trachomati
suscept
macrolid
tetracyclin
quinolon
sulfonamid
erythromycin
week
treatment
choic
neonat
pneumonia
mycoplasma
pneumonia
chlamydia
pneumonia
play
greater
role
caus
respiratori
tract
diseas
children
previous
thought
indol
cours
develop
day
manifest
lowgrad
fever
scratchi
sore
throat
ach
headach
character
pathogen
day
rale
may
heard
particularli
base
infiltr
tend
occur
organ
associ
initi
promot
exacerb
asthma
children
addit
pertussislik
ill
acut
bronchiti
describ
recent
studi
shown
nearli
half
case
communityacquir
pneumonia
children
age
year
associ
pneumonia
c
pneumonia
classic
atyp
pneumonia
caus
organ
usual
mild
selflimit
howev
number
studi
suggest
sever
pulmonari
infect
may
occur
otherwis
healthi
children
pleural
effus
pneumatocoel
lung
abscess
pneumothorac
bronchiectasi
chronic
interstiti
fibrosi
acut
respiratori
distress
syndrom
although
rare
complic
report
serolog
test
common
mean
diagnosi
often
retrospect
cultur
obtain
swab
nasopharynx
may
take
sever
day
grow
pcr
techniqu
current
refin
standard
treatment
antibiot
reduc
rate
recurr
wheez
episod
decreas
morbid
shorten
durat
symptom
organ
suscept
tetracyclin
macrolid
quinolon
optim
dose
durat
treatment
unclear
howev
data
suggest
prolong
treatment
greater
week
may
desir
decreas
symptom
erad
organ
nasopharynx
mycoplasma
pneumonia
chlamydia
pneumonia
increas
preval
older
children
staphylococcu
aureu
gramposit
organ
found
skin
nasal
mucosa
mucu
membran
children
carrier
gener
spread
direct
contact
respiratori
particl
aureu
unusu
caus
lower
airway
diseas
otherwis
healthi
children
typic
isol
infant
young
children
debilit
condit
primari
aureu
pneumonia
present
winter
earli
spring
short
febril
prodrom
rapid
onset
pulmonari
symptom
blood
cultur
posit
patient
secondari
staphylococc
pneumonia
prolong
prodrom
season
predilect
often
seen
influenza
infect
secondari
pneumonia
usual
result
hematogen
spread
blood
cultur
posit
patient
unilater
lobar
diseas
typic
primari
diseas
diffus
bilater
infiltr
frequent
secondari
pneumonia
effus
diagnos
children
present
ultim
develop
case
pneumatocoel
occur
children
treatment
nafcillin
oxacillin
organ
becom
resist
requir
therapi
seriou
invas
diseas
vancomycin
linezolid
daptomycin
quinupristindalfopristin
staphylococcu
aureu
pneumonia
uncommon
effus
ultim
develop
case
pneumatocoel
occur
methicillin
resist
staphylococcu
aureu
mrsa
consid
restrict
hospit
longterm
care
facil
howev
commun
acquir
mrsa
camrsa
signific
caus
varieti
infect
includ
pneumonia
children
without
prior
health
care
facil
exposur
major
commun
acquir
mrsa
infect
involv
minor
skin
soft
tissu
infect
invas
sometim
fatal
infect
occur
otherwis
healthi
individu
camrsa
healthcareassoci
mrsa
hamrsa
distinguish
sever
import
featur
patient
camrsa
definit
recent
hospit
acut
chronic
care
prolong
antibiot
use
chronic
underli
diseas
toxin
product
also
distinguish
camrsa
hamrsa
panton
valentin
leukocidin
pvl
toxin
present
camrsa
isol
rare
hamrsa
isol
pvl
toxin
lyse
white
blood
cell
lead
leukopenia
decreas
abil
kill
aureu
product
implic
contributor
develop
camrsa
necrot
pneumonia
camrsa
isol
unlik
hamrsa
lack
multidrug
resist
camrsa
gener
suscept
clindamycin
trimethoprimsulfamethoxazol
doxycyclin
hamrsa
probabl
hamrsa
develop
resist
surviv
healthcar
set
group
betahemolyt
streptococcu
gabh
gramposit
organ
respons
pharyng
tonsil
children
rare
primari
caus
pneumonia
occur
children
gener
high
fever
appear
toxic
pneumonia
typic
lobar
associ
empyema
common
pneumatocoel
may
develop
sever
virul
toxinproduc
gabh
mserotyp
associ
toxic
shock
syndrom
preexist
varicella
diseas
disrupt
skin
soft
tissu
port
entri
report
approxim
time
associ
pneumonia
occur
children
toxic
shock
syndrom
gabh
highli
suscept
penicillin
cephalosporin
case
toxic
shock
clindamycin
often
ad
inhibit
product
streptococc
pyrogen
exotoxin
spea
b
speb
infant
perinat
acquir
group
b
streptococcu
gb
infect
pneumonia
infant
usual
system
diseas
blood
cultur
frequent
posit
lateonset
gb
predominantli
caus
type
iii
serotyp
infant
infect
usual
manifest
bacteremia
without
focu
mening
pneumonia
rare
lateonset
diseas
gb
uniformli
sensit
penicillin
pertussi
whoop
cough
highli
contagi
respiratori
tract
infect
caus
gramneg
pleomorph
bacillu
bordetella
pertussi
less
commonli
bordetella
parapertussi
develop
widespread
use
vaccin
signific
sustain
decreas
incid
occur
howev
despit
immun
rate
greater
cyclic
recurr
diseas
occur
everi
year
sinc
like
secondari
wane
immun
adolesc
young
adult
underimmun
unimmun
infant
vulner
nearli
death
report
pertussi
occur
infant
younger
month
age
pertussi
often
divid
catarrah
fever
rhinnorhea
initi
cough
paroxysm
sever
cough
episod
lymphocytosi
potenti
complic
convalesc
stage
slow
wane
cough
week
month
complic
includ
secondari
bacteri
viral
pneumonia
apnea
malnutrit
pulmonari
hypertens
neurolog
involv
includ
seizur
encephalopathi
infant
less
month
age
highest
risk
complic
mortal
characterist
paroxysm
cough
end
inspiratori
whoop
occur
children
infant
may
present
nonspecif
cough
associ
apnea
cyanosi
without
whoop
adolesc
may
asymptomat
mild
prolong
cough
increas
white
blood
count
lymphocytosi
characterist
earli
cours
diseas
prefer
test
laboratori
confirm
detect
b
pertussi
dna
pcr
assay
bacteriolog
cultur
provid
definit
diagnosi
administ
earli
stage
diseas
first
day
ill
erythromycin
day
may
decreas
symptom
reduc
risk
spread
day
cours
azithromycin
day
cours
clarithromycin
found
effect
less
gastrointestin
symptom
corticosteroid
bronchodil
intraven
immunoglobulin
demonstr
efficaci
support
care
supplement
oxygen
mechan
ventil
intraven
fluid
mainten
adequ
calor
intak
treatment
secondari
bacteri
infect
mainstay
therapi
use
extracorpor
membran
oxygen
infant
hypoxemia
pulmonari
hypertens
right
heart
failur
refractori
convent
mechan
ventil
result
poorer
outcom
expect
vaccin
infanc
booster
dose
adolesc
prevent
influenza
main
viral
caus
pneumonia
schoolag
children
requir
hospit
three
serotyp
b
c
divid
subtyp
base
hemagglutinin
neuraminidas
gene
hemagglutinin
neuraminidas
typic
infect
human
gene
segment
surfac
glycoprotein
unstabl
mutat
call
antigen
shift
occur
regularli
epidem
occur
annual
winter
month
short
day
incub
period
viru
caus
destruct
ciliat
respiratori
epithelium
within
day
symptom
airway
edema
infiltr
inflammatori
cell
airway
mucosa
epithelium
follow
slow
repair
occur
week
sever
fulmin
pneumonia
may
result
hemorrhag
exud
contain
mani
polymorphonuclear
mononuclear
cell
destruct
respiratori
epithelium
often
lead
secondari
bacteri
infect
although
death
influenza
pneumonia
uncommon
signific
number
children
die
previous
healthi
influenza
season
influenzarel
death
occur
children
less
year
age
fortyf
percent
older
children
year
age
underli
medic
condit
rare
complic
influenza
includ
acut
myositi
rhabdomyolysi
myocard
pericard
rey
syndrom
enceph
transvers
myeliti
syndrom
children
may
present
abrupt
clinic
cours
manifest
high
fever
myalgia
headach
scratchi
sore
throat
dri
cough
peripher
white
blood
count
usual
less
pulmonari
infiltr
often
involv
multipl
lobe
bacteri
coinfect
especi
mrsa
increas
morbid
mortal
significantli
rimantidin
amantadin
shorten
cours
influenza
type
diseas
limit
viral
replic
given
within
first
h
diseas
prophylact
dose
effect
interfer
antibodi
product
vaccin
drug
central
nervou
system
gastrointestin
side
effect
includ
increas
incid
seizur
oseltamivir
zanamivir
recent
approv
treatment
influenza
infect
children
inhibit
neuraminidas
enzym
produc
influenza
b
cours
diseas
healthi
adult
reduc
day
start
within
h
onset
symptom
zanamivir
dri
powder
aerosol
must
deliv
special
breathactiv
devic
bronchospasm
patient
asthma
report
aspirin
aspirincontain
product
avoid
due
risk
rey
syndrom
immunoprophylaxi
effect
strategi
prevent
influenza
infect
inactiv
vaccin
efficaci
rate
current
inactiv
vaccin
recommend
children
older
month
age
high
risk
condit
includ
chronic
pulmonari
cardiac
diseas
immunosuppress
disord
sickl
cell
diseas
hemoglobinopathi
diseas
requir
longterm
aspirin
therapi
chronic
metabol
renal
diseas
healthi
children
age
month
household
contact
age
month
high
risk
person
live
attenu
influenza
vaccin
licens
administ
intranas
rout
approv
healthi
children
age
year
although
antivir
medic
may
attenu
cours
influenza
given
earli
immunoprophylaxi
vaccin
effect
strategi
control
influenza
infect
avian
influenza
virus
normal
infect
speci
bird
pig
howev
first
human
death
avian
influenza
occur
hong
kong
year
old
rey
syndrom
subsequ
epidem
occur
among
human
hong
kong
close
contact
live
infect
poultri
subtyp
appear
omin
due
abil
rapidli
mutat
infect
new
speci
overal
mortal
rate
greater
avian
virus
believ
transmiss
persontoperson
recent
case
investig
possibl
children
uniformli
present
fever
cough
symptom
rang
typic
influenzalik
symptom
conjunct
respiratori
diseas
failur
signific
laboratori
data
includ
leukopenia
thrombocytopenia
children
develop
pneumonia
progress
ard
die
diagnosi
remain
difficult
test
wide
avail
antivir
drug
avail
influenza
recent
strain
southeast
asia
resist
rimantadin
amantadin
therefor
treatment
mainli
support
prototyp
vaccin
made
avail
manufactur
april
product
difficult
standard
mean
produc
influenza
vaccin
special
grown
chicken
egg
feasibl
kill
embryo
enough
virus
harvest
vaccin
product
avian
influenza
occur
epidem
among
person
close
contact
live
infect
poultri
children
pneumonia
progress
ard
succumb
diseas
april
center
diseas
control
confirm
emerg
novel
influenza
viru
gene
swine
virus
eurasian
lineag
gene
avian
influenza
virus
june
first
influenza
pandem
sinc
declar
affect
countri
territori
comparison
ill
season
influenza
major
case
occur
individu
younger
year
age
nearli
half
case
occur
children
year
age
clinic
symptom
typic
influenza
fever
sore
throat
cough
muscl
ach
addit
vomit
diarrhea
children
wide
rang
complic
report
includ
mildtomoder
otiti
media
sinus
myositi
febril
seizur
sever
complic
myocard
rhabdomyolysi
enceph
sever
complic
may
frequent
involv
invas
bacteri
coinfect
ie
mrsa
andor
exacerb
underli
medic
condit
particular
asthma
children
present
initi
uncompl
influenza
may
rapidli
progress
hypoxem
respiratori
failur
multiorgan
system
dysfunct
refractori
therapi
fig
report
death
approxim
children
major
children
comorbid
asthma
neurodevelopment
condit
obes
american
academi
pediatr
work
group
identifi
children
greatest
risk
lifethreaten
influenza
diseas
tabl
center
diseas
control
recommend
prompt
empir
antivir
therapi
infant
children
adolesc
age
present
suspect
confirm
influenza
follow
condit
ill
requir
hospitalizationprogress
sever
complic
ill
regardless
previou
healthpres
signific
risk
factor
see
tabl
strain
found
resist
amantadin
rimantadin
usual
sensit
neuraminidas
inhibitor
specif
oseltamivir
zanamir
oseltamivir
emerg
approv
treatment
children
less
month
age
resist
oseltamivir
report
thought
due
mutat
interestingli
mutat
confer
resist
oseltamivir
zanamivir
peramivir
neuraminidas
inhibitor
unapprov
investig
antivir
avail
intraven
formul
receiv
emerg
use
author
permit
fda
use
children
confirm
sever
refractori
influenza
use
restrict
children
respond
either
oral
inhal
antivir
drug
parenter
rout
depend
method
drug
deliveri
vaccin
manufactur
licens
use
standard
season
influenza
late
singl
dose
found
provid
adequ
protect
children
older
year
age
younger
children
requir
two
dose
separ
least
day
adenovirus
implic
pneumonia
children
adenovirus
classifi
serotyp
type
common
etiolog
agent
lower
respiratori
diseas
caus
sever
necrot
pneumon
serotyp
associ
seriou
pulmonari
sequela
bronchiectasi
bronchiol
obliteran
unilater
hyperluc
lung
persist
abnorm
pulmonari
function
test
adenoviru
infect
peak
month
year
age
mortal
sever
respiratori
infect
high
diseas
often
involv
multipl
organ
system
survivor
may
perman
lung
injuri
often
form
bronchiol
obliteran
immunocompromis
host
mortal
rate
high
cidofovir
vitro
activ
adenoviru
proof
efficaci
limit
therapi
support
mortal
adenoviru
infect
remain
high
multipl
organ
system
involv
sever
acut
respiratori
syndrom
newli
describ
pulmonari
infect
caus
novel
sarsassoci
coronaviru
sarscov
highli
contagi
coin
first
plagu
twentyfirst
centuri
diseas
rapidli
spread
among
household
contact
healthcar
personnel
children
less
year
age
account
approxim
affect
mean
age
year
death
report
among
children
outbreak
children
adult
present
fever
malais
cough
coryza
chill
rigor
sputum
product
headach
myalgia
leukopenia
lymphopenia
thrombocytopenia
mildli
elev
activ
partial
thromboplastin
time
elev
level
lactat
dehydrogenas
radiograph
chest
show
nonspecif
infiltr
apart
diarrhea
patient
minim
extrapulmonari
symptom
earli
diagnosi
revers
transcriptionpolymeras
chain
reaction
rtpcr
made
sensit
nasopharyng
aspir
within
first
day
ill
clinic
cours
follow
triphas
pattern
incub
period
day
prodrom
high
fever
chill
malais
headach
myalgia
diarrhea
occur
adult
day
diseas
progress
involv
lower
airway
dri
nonproduct
cough
dyspnea
case
acut
respiratori
distress
syndrom
ard
follow
often
patient
requir
mechan
ventil
death
occur
respiratori
failur
young
children
run
milder
shorter
biphas
clinic
cours
cough
found
approxim
half
children
crackl
rare
heard
despit
radiograph
evid
infiltr
regimen
antibiot
ribavirin
corticosteroid
propos
base
initi
anecdot
success
howev
ribavirin
demonstr
minim
activ
sarscov
isol
vitro
nonrandom
studi
corticosteroid
report
favor
outcom
pediatr
seri
children
confirm
sar
treat
ribavirin
corticosteroid
show
advers
effect
surviv
sar
rare
affect
children
morbid
less
report
mortal
hantaviru
cardiopulmonari
syndrom
viral
zoonot
diseas
affect
healthi
children
adolesc
expos
aerosol
rodent
excreta
deer
mous
main
rodent
reservoir
case
occur
southwestern
unit
state
case
confirm
state
hcp
present
prodrom
fever
chill
myalgia
headach
gastrointestin
symptom
respiratori
compromis
requir
supplement
oxygen
gener
occur
within
h
diseas
progress
respiratori
distress
ard
major
death
result
hypoxemia
cardiac
dysfunct
mark
hypotens
ventricular
arrhythmia
adult
case
fatal
rate
approxim
recent
case
seri
children
age
year
reveal
infect
children
develop
hcp
die
critic
ill
requir
mechan
ventil
treatment
support
ribavirin
proven
reduc
mortal
extracorpor
membran
oxygen
use
two
patient
one
surviv
laboratori
evalu
reveal
thrombocytopenia
leukocytosi
circul
immunoblast
elev
prothrombin
time
predict
sever
diseas
death
report
children
younger
year
age
diagnosi
made
detect
hantavirusspecif
immunoglobulin
hantavirusspecif
rna
polymeras
chain
reaction
hantaviru
antigen
immunohistochemistri
hantaviru
rare
infant
schoolag
children
death
report
children
less
year
age
pneumocysti
carinii
known
pneumocysti
jiroveci
opportunist
pulmonari
pathogen
infant
children
human
immunodefici
viru
hiv
primari
immunodefici
malnutrit
hematolog
malign
solid
organ
bone
marrow
transplant
recipi
patient
high
dose
corticosteroid
therapi
inflammatori
collagenvascular
diseas
unicellular
organ
exist
cyst
diagnost
form
organ
attach
type
alveolar
cell
result
alveol
character
ventilationperfus
mismatch
decreas
pulmonari
complianc
untreat
pcp
carri
mortal
rate
nearli
hivseroposit
child
fortun
incid
markedli
decreas
administr
chemoprophylact
agent
high
risk
patient
children
typic
present
fever
tachypnea
nonproduct
cough
hypoxia
absenc
rale
auscult
chest
initi
may
elev
ph
low
carbon
dioxid
level
lactat
dehydrogenas
level
gener
elev
bilater
diffus
alveolar
infiltr
seen
initi
hilar
involv
subsequ
spread
peripheri
fig
diagnosi
made
demonstr
organ
methenamin
silver
nitrat
stain
pulmonari
tissu
respiratori
secret
lung
fluid
bronchoalveolar
lavag
wide
use
techniqu
obtain
lung
fluid
diagnosi
treatment
consist
support
therapi
supplement
oxygen
ultim
continu
posit
airway
pressur
mechan
ventil
may
necessari
respiratori
failur
occur
trimethoprimsulfamethoxazol
tmpsmx
recommend
initi
treatment
patient
toler
tmpsmx
pentamidin
isoethion
use
corticosteroid
antiinflammatori
dose
adjunct
antimicrobi
therapi
improv
clinic
outcom
concurr
pulmonari
infect
found
patient
frequent
bacteri
cytomegaloviru
pneumonia
determin
etiolog
agent
pneumonia
difficult
fortun
pneumonia
identif
specif
caus
organ
critic
howev
children
complic
cours
fail
respond
standard
therapi
definit
diagnosi
etiolog
agent
essenti
complet
blood
count
inflammatori
marker
chest
radiograph
differenti
caus
agent
pneumonia
blood
cultur
rare
posit
outsid
neonat
period
rapid
antigen
test
avail
rsv
parainfluenza
influenza
adenoviru
nasopharyng
swab
viral
cultur
gener
take
day
becom
posit
one
studi
patient
discharg
prior
posit
result
older
children
adolesc
might
abl
produc
sputum
gram
stain
cultur
adequ
specimen
contain
leukocyt
fewer
squamou
epitheli
cell
per
lowpow
field
intub
patient
sputum
easili
acquir
howev
interpret
result
gram
stain
cultur
time
difficult
differenti
colon
patholog
organ
colon
endotrach
tube
may
occur
earli
h
frequent
h
oropharynx
becom
colon
within
h
stomach
h
lower
respiratori
tract
h
addit
comparison
infecti
agent
isol
tracheal
aspir
bronchoalveolar
lavag
found
concord
bronchoalveolar
lavag
bal
safe
use
obtain
secret
lower
airway
gram
stain
cultur
especi
use
diagnosi
pneumonia
immunocompromis
child
howev
bal
perform
directli
bronchoscop
carri
risk
contamin
smallest
bronchoscop
accommod
protect
specimen
brush
mm
requir
mm
endotrach
tube
passag
smallest
flexibl
fiberopt
bronchoscop
suction
channel
extern
diamet
mm
small
admit
doublesheath
brush
nonbronchoscop
doublelumen
plug
cathet
insert
blindli
endotrach
tube
obtain
noncontamin
specimen
sensit
specif
sampl
similar
obtain
bronchoscop
guid
protect
specimen
transthorac
needl
aspir
perform
center
good
result
one
studi
report
diagnost
success
rate
patient
incid
pneumothorax
approxim
none
requir
subsequ
placement
pleural
drainag
cathet
lung
biopsi
rare
need
make
definit
diagnosi
support
treatment
oxygen
intraven
fluid
often
standard
therapi
pneumonia
mechan
ventil
caus
elev
antidiuret
hormon
level
care
fluid
monitor
essenti
avoid
overhydr
excess
lung
water
hyponatremia
initi
antibiot
choic
empir
base
upon
like
organ
age
group
difficulti
identifi
caus
agent
child
respiratori
statu
includ
respiratori
rate
work
breath
puls
oximetri
central
nervou
system
respons
close
monitor
noninvas
bilevel
posit
airway
pressur
bipap
effect
use
children
mild
moder
respiratori
insuffici
defin
aa
gradient
ratio
mm
hg
serial
evalu
maskfac
contact
area
essenti
avoid
skin
breakdown
noninvas
bipap
ventil
effect
children
moder
respiratori
insuffici
children
moder
sever
respiratori
insuffici
often
requir
intub
mechan
ventil
children
respiratori
failur
secondari
pneumonia
often
requir
increas
posit
end
expiratori
pressur
peep
increas
inspiratori
time
aggress
pulmonari
toilet
recruit
alveoli
patient
requir
high
level
peep
adequ
sedat
often
requir
prevent
patientventil
asynchroni
barotrauma
spontan
respir
encourag
mechan
ventil
rare
use
neuromuscular
blockad
requir
allow
mechan
ventil
prone
posit
may
improv
ventilationperfus
vq
mismatch
depend
lung
region
lung
protect
strategi
allow
permiss
hypercapnea
small
lung
volum
ventil
appropri
peep
maintain
alveolar
recruit
recommend
children
pneumonia
high
frequenc
oscillatori
ventil
also
util
maintain
mean
airway
pressur
alveolar
recruit
airway
pressur
releas
ventil
aprv
provid
recruit
alveoli
allow
spontan
respir
children
sever
respiratori
distress
syndrom
treatment
bovin
surfact
may
improv
oxygen
extracorpor
life
support
continu
role
children
revers
sever
acut
hypoxem
respiratori
failur
refractori
mechan
ventil
pneumonia
often
complic
develop
pleural
effus
empyema
occur
fluid
product
interstiti
lung
tissu
exce
maximum
pleural
lymphat
flow
parapneumon
effus
often
occur
pneumonia
white
blood
cell
debri
infect
block
lymphat
result
elev
protein
pleural
space
increas
colloid
osmot
pressur
consequ
failur
fluid
reabsorpt
physic
exam
child
decreas
breath
sound
effus
older
children
auscultatori
percuss
chang
might
appreci
plain
chest
radiograph
reveal
clinic
signific
effus
ultrasound
chest
comput
tomogram
use
determin
volum
qualiti
fluid
presenc
locul
simpl
parapneumon
effus
transud
also
differenti
exud
use
criteria
light
et
al
tabl
pleural
fluid
ph
less
indic
complic
effus
like
exud
requir
drainag
wherea
pleural
fluid
ph
suggest
effus
may
manag
system
antibiot
alon
complic
parapneumon
effus
empyema
occur
fluid
becom
purul
stage
effus
undergo
fibrinopurul
stage
mani
polymorphonuclear
leukocyt
bacteria
cellular
debri
enter
fluid
fibrin
deposit
pleural
surfac
locul
begin
form
ph
glucos
level
fall
ldh
level
rise
untreat
often
progress
third
organ
stage
exud
develop
inelast
fibrot
peel
restrict
lung
simpl
parapneumon
effus
usual
resolv
thoracentesi
tube
thoracostomi
antibiot
treatment
pneumonia
complic
parapneumon
effus
success
treat
thoracotomi
tube
fibrinolyt
howev
although
risk
bleed
reportedli
low
therapi
requir
close
monitor
chest
tube
drainag
instil
expens
medic
intermitt
clamp
chest
tube
singl
recommend
choic
fibrinolyt
agent
dosag
establish
also
tri
late
organ
phase
often
unsuccess
due
locul
high
viscos
purul
fluid
surgic
debrid
either
open
procedur
videoassist
thorascop
surgeri
vat
often
need
organ
complic
parapneumon
effus
multipl
studi
report
earli
vat
thoracotomi
empyema
lead
shorter
hospit
stay
treatment
modal
best
determin
tempor
stage
natur
effus
videoassist
thorascop
surgeri
vat
treatment
empyema
associ
shorter
hospit
stay
acut
pulmonari
infect
common
diagnos
requir
admiss
pediatr
intens
care
unit
understand
pathophysiolog
lower
respiratori
infect
enabl
intensivist
tailor
therapi
individu
child
pathogen
earli
establish
specif
etiolog
select
correct
treatment
plan
directli
impact
clinic
outcom
month
old
former
week
prematur
infant
bronchopulmonari
dysplasia
present
clinic
sign
bronchiol
analysi
nasopharyng
secret
polymeras
chain
reaction
test
identifi
respiratori
synciti
viru
follow
therapi
proven
consist
benefit
rsv
bronchiol
aaminophyllinebbronchodilatorsccorticosteroidsdribavirinesupport
care
palivizumab
indic
follow
children
aa
month
old
former
week
prematur
infant
underw
surgic
repair
larg
ventricular
septal
defect
receiv
palivizumab
week
agoba
month
old
former
week
prematur
infant
mild
bronchopulmonari
dysplasia
receiv
palivizumab
week
agoca
month
old
former
week
prematur
infant
peripher
pulmon
stenosi
never
receiv
palivizumabda
month
old
full
term
infant
urea
cycl
defect
never
receiv
palivizumabean
month
old
former
week
prematur
infant
bronchopulmonari
dysplasia
receiv
fifth
dose
palivizumab
month
ago
year
old
unimmun
male
moder
sever
asthma
requir
hospit
admiss
h
histori
fever
cough
myalgia
middl
influenza
outbreak
appropri
initi
manag
child
includ
follow
aintraven
peramivir
administ
confirm
diagnosi
rapid
testingbintraven
zanamivir
administ
soon
possiblecor
amantidin
administ
soon
possibledor
oseltamivir
administ
soon
possibleeor
inhal
zanamivir
administ
confirm
diagnosi
rapid
test
year
old
present
high
fever
respiratori
distress
parapneumon
effus
chest
radiograph
follow
find
would
like
suggest
need
videoassist
thorascop
surgic
drainag
effus
aa
mediastin
shift
away
effusionba
pleural
fluid
ph
glucos
mgdlcpersist
drainag
day
percutaneouslyplac
thoracentesi
catheterdth
persist
fever
follow
h
parenter
antibioticseth
presenc
locul
ultrasound
comput
tomographi
imag
year
old
male
present
acut
hypoxem
respiratori
failur
ratio
dissemin
intravascular
coagul
renal
insuffici
secondari
catecholeamineresist
shock
rapid
antigen
test
identifi
viru
addit
oral
oseltamivir
initi
antimicrobi
coverag
includ
follow
acefepimebintraven
immunoglobulincintraven
zanamivirdtrimethoprimsulfamethoxazoleevancomycin
year
old
male
present
day
histori
fever
chill
myalgia
headach
gastrointestin
symptom
clinic
exam
febril
tachypn
scatter
rale
hypotens
rash
evid
anim
bite
exam
initi
laboratori
result
remark
thrombocytopenia
leukocytosi
increas
percentag
circul
immunoblast
elev
level
lactat
dehydrogenas
aspart
aminotransferas
alanin
aminotransferas
prothrombin
time
admit
respiratori
statu
continu
deterior
ultim
requir
mechan
ventil
remain
refractori
shock
sever
day
extens
diagnost
workup
diagnos
hantaviru
cardiopulmonari
syndrom
base
detect
hantavirusspecif
immunoglobulin
follow
like
part
medic
histori
aan
underli
immunodeficiencybb
member
high
school
wrestl
teamcexposur
rodent
excrementdintraven
drug
useeresid
southeastern
unit
state
corticosteroid
establish
benefit
follow
clinic
scenario
aa
week
old
infant
sever
bronchiol
secondari
respiratori
synciti
virusba
month
old
unimmun
infant
sever
hypoxia
respiratori
failur
secondari
pertussisca
year
old
femal
necrot
pneumonia
secondari
commun
acquir
methicillin
resist
staphylococcu
aureu
da
month
old
histori
acquir
immun
defici
syndrom
current
hypox
respiratori
failur
secondari
pneumocysti
jiroveci
pneumonia
pneumocysti
carinii
pneumonia
ea
year
old
nativ
american
femal
sever
cardiopulmonari
dysfunct
secondari
hantaviru
infect
eadeecd
